The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
Background
Research works printed but not linked: 4
- 23. Mukhopadhyay S. Nano drugs: A critical review of their patents and market. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Ltd.; Amsterdam, The Netherlands: 2019. pp. 523–551.
- 39. Elsadek N.E., Abu Lila A.S., Ishida T. 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. In: Pasut G., Zalipsky S., editors. Polymer-Protein Conjugates. Elsevier; Amsterdam, The Netherlands: 2020. pp. 103–123.
- 47. Seppälä J.T.S., Mäkelä O. Hapten. In: Roitt I., Delves P., editors. Encyclopedia of Immunology. 2nd ed. Elsevier Ltd.; Amsterdam, The Netherlands: 1998. pp. 1050–1052.
- 72. Abbina S., Parambath A. PEGylation and its alternatives: A summary. In: Parambath A., editor. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol. Elsevier Ltd.; Amsterdam, The Netherlands: 2018. pp. 363–376.
Cited by
Items 401–500 of 669
Hussen, B. M., Abdullah, S. R., Khudhur, Z. O., Samsami, M., & Taheri, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145088 · Cited by 9
Marx, V., Mochida, Y., Osawa, S., Tockary, T. A., Norimatsu, J., Yokoo, H., Oba, M., & Uchida, S. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c00636 · Cited by 8
Synthesis and Characterization of Biocompatible Sulfoxide-Containing Molecular Bottlebrushes
Olszewski, M., Phạm, D. A., Bolívar, S. G., Rabanel, J., Martinez, M. R., Matyjaszewski, K. A., & Banquy, X. (2022) · ACS Applied Polymer Materials · doi:10.1021/acsapm.2c01468 · Cited by 9
Pizzi, D., Humphries, J., Morrow, J. P., Mahmoud, A., Fletcher, N. L., Sonderegger, S., Bell, C. A., Thurecht, K. J., & Kempe, K. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c01105 · Cited by 8
Soares, S., Pereira, C., Sousa, A. P., Rocha, A. C., Sales, M. G. F., Correa‐Duarte, M. A., Guerreiro, S. G., & Fernandes, R. (2023) · Cells · doi:10.3390/cells12050787 · Cited by 10
“Besides, PEG contributes to reduced immunogenicity and elimination by clearance of AuNPs, increasing their circulation time in blood [28,34].”
BackgroundPouyan, P., Zemella, A., Schloßhauer, J. L., Walter, R. M., Haag, R., & Kubick, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-33463-x · Cited by 8
Xia, Q., Shen, J., Ding, H., Liu, S., Li, F., Li, F., & Feng, N. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2268512 · Cited by 8
“Anti-PEG antibodies have been witnessed in patients and experimental animals, accelerating the blood clearance (termed ABC phenomenon) of PEGylated nanomedicines by activating complement after absorption on the nano-surface [144].”
BackgroundCharge-Complementary Polymersomes for Enhanced mRNA Delivery
Kim, H., Ahn, Y., Kim, M., Choi, J., Shin, S., & Kim, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122781 · Cited by 9
“ChargeSomes are composed of polyethylene glycol (PEG), a polymer known for its biocompatibility [38].”
BackgroundGibson, V. P., Tahiri, H., Gilbert, C., Yang, C., Phan, Q. T., Banquy, X., & Hardy, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040563 · Cited by 8
“Additionally, the antifouling properties of hyaluronic acid might be of interest in the field where PEG-replacing strategies have been discussed [37–40].”
BackgroundDevice Processing Challenges for Miniaturized Sensing Systems Targeting Biological Fluids
Stoukatch, S., Dupont, F., & Redouté, J. (2022) · Biomedical Materials & Devices · doi:10.1007/s44174-022-00034-z · Cited by 8
Negrão, C. V. Z. D. V., Cerize, N. N. P., Justo-Júnior, A. D. S., Liszbinski, R. B., Meneguetti, G. P., de Araújo, L. M. S., Rocco, S. A., Gonçalves, K. D. A., Cornejo, D. R., Léo, P., et al. (2024) · Nanomedicine · doi:10.2217/nnm-2023-0225 · Cited by 8
Low-Fouling Gold Nanorod Theranostic Agents Enabled by a Sulfoxide Polymer Coating
Chang, Y.-X., Wang, Q., Xu, W., Huang, X., Xu, X., Han, F. Y., Qiao, R., Ediriweera, G. R., Peng, H., Fu, C., et al. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00696 · Cited by 8
Fuentes, S., Arancibia, D., Rojas, M., Carmona, F., Ortega, A., Valenzuela, J., Hernández‐Álvarez, C., & Martin, I. R. (2024) · ACS Omega · doi:10.1021/acsomega.4c00974 · Cited by 8
Glycerol‐Based Copolyesters as Polymeric Nanocarriers for Drug Delivery
D’Anna, P., Jacob, P. L., Axioti, E., Alvey, K. E., Berfi, N. A., Pearce, J. E., Cavanagh, R. J., Chauhan, V. M., Taresco, V., & Conte, C. (2024) · Journal of Polymer Science · doi:10.1002/pol.20240762 · Cited by 7
Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment
Nawaz, A., Ariffin, N. S., & Wong, T. W. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101041 · Cited by 14
“Further, the PEGylated CS NPs of CRISPR-Cas9 risks binding and removal by anti-PEG immunoglobulin [ 47 ,184 ].”
Overcoming PEG Antigenicity: Statistical PEG Isomers Reduce Antibody Binding
Deuker, M., Schulz, D., Koynov, K., Morsbach, S., Frey, H., & Landfester, K. (2025) · Advanced Science · doi:10.1002/advs.202521061 · Cited by 12
Pyzhov, V. S., Бахрушина, Е. О., Gegechkori, V., Smirnov, V. V., Evzikov, G. Y., Kartashova, A. K., Zubareva, I. M., Krasnyuk, I. I., & Краснюк, И. И. (2026) · Polymers · doi:10.3390/polym18060681 · Cited by 10
“This polymer class is distinguished by high stability and chemical versatility: the presence of active terminal groups allows for directed conjugate synthesis with drugs or targeting ligands [118].”
Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics
Gustafson, K. T., Mokhtari, N., Manalo, E. C., Mira, J. M., Gower, A., Yeh, Y., Vaidyanathan, M., Esener, S. C., & Fischer, J. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010143 · Cited by 8
Borova, S., & Luxenhofer, R. (2023) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.19.21 · Cited by 7
Review: Syntheses of poly(lactic acid)s and their block copolymers for drug delivery applications
Oktavia, L. W., Bégué, D., Campana, P. T., & Hiorns, R. C. (2023) · Polymer International · doi:10.1002/pi.6529 · Cited by 7
Altering the bio-inert properties of surfaces by fluorinated copolymers of mPEGMA
Koguchi, R., Jankova, K., Tanaka, Y., Yamamoto, A., Murakami, D., Yang, Q., Ameduri, B. M., & Tanaka, M. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213573 · Cited by 9
Salehi, T., Estabragh, M. A. R., Salarpour, S., Ohadi, M., & Dehghannoudeh, G. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2271680 · Cited by 9
Elter, J. K., Liščáková, V., Moravec, O., Vragović, M., Filipová, M., Štěpánek, P., Šácha, P., & Hrubý, M. (2024) · Macromolecules · doi:10.1021/acs.macromol.3c02600 · Cited by 7
Efficient siRNA delivery to murine melanoma cells via a novel genipin-based nano-polymer
Pelle, G. D., Božič, T., Vukomanović, M., Serša, G., Markelc, B., & Kostevšek, N. (2024) · Nanoscale Advances · doi:10.1039/d4na00363b · Cited by 7
Zwitterionic alginate derivative as a new delivery platform for enhanced blood circulation
Lee, H., Li, Y. R., Bao, K., Lee, S. S., Kang, H., Choi, H. S., & Choi, Y. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00703-9 · Cited by 8
“However, despite of wide spread use, PEG has several drawbacks, including poor stability, accumulated toxicity, and immunogenicity induced by repeated injections (Hoang Thi et al. 2020; Knop et al. 2010).”
Immunology of biodegradable nanoparticles: a brief overview on a wide growing field
Pisani, A., & Bardi, G. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00006 · Cited by 9
Wu, Y., Hu, F., Yang, X., Zhang, S., Jia, C., Liu, X., & Zhang, X. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2134395 · Cited by 7
kharazmi, A., & Attaran, N. (2023) · IET Nanobiotechnology · doi:10.1049/nbt2.12121 · Cited by 7
Weaver, E., Macartney, R. A., Irwin, R., Uddin, S., Hooker, A., Burke, G. A., Wylie, M. P., & Lamprou, D. A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123710 · Cited by 7
Kimura, S., & Harashima, H. (2024) · BioDrugs · doi:10.1007/s40259-024-00647-4 · Cited by 9
“This immune response is associated with the development of a severe accelerated blood clearance (ABC) phenomenon and hypersensitivity reactions, and several studies have been conducted for developing PEG alternatives, such as poly(N-vinylpyrrolidone) (PVP) and polysarcosine [90–93].”
Copolymer-Coated Au–Pt Nanomotors for Delivery of Disulfiram Prodrug
Kamankesh, M., Aghmiouni, D. K., & Khoee, S. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c00318 · Cited by 7
Exploring the potential of polypeptide–polypeptoide hybrid nanogels for mucosal delivery
Xu, T., Skoulas, D., Ding, D., Cryan, S., & Heise, A. (2022) · Polymer Chemistry · doi:10.1039/d2py01126c · Cited by 7
Cho, W. H., Kim, H., Yoo, S., Lee, S. M., Kim, T. J., & Lee, J. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00733-x · Cited by 9
“…(PGs), poly(hydroxyethyl methacrylate), poly( N , N -dimethyl acrylamide), and poly( N -(2-hydroxypro-pyl) methacrylamide) have shown great promise as alternatives to PEG for reducing immunogenicity and enhancing uricase stability (Knop et al. 2010; Khutoryanskiy 2018; Hoang Thi et al. 2020).”
Self-citationYeshchenko, O. A., Daoud, L., Khort, P. S., Fedotov, O., Zinoune, J.-B., Boudebs, G., Breton, T., Passirani, C., Saulnier, P., & Krupka, O. (2025) · Nanoscale Advances · doi:10.1039/d5na00243e · Cited by 6
The Recombinant Antibodies & Mimetics Database: Redefining the future of antibody use in science
Modi, S. (2025) · Alternatives to Laboratory Animals · doi:10.1177/02611929251371129 · Cited by 6
Randhawa, G., Kostashuk, M., Pan, Z., Nordstrom, N., Kalab, T., Winterhelt, E., & Hoare, T. R. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502866 · Cited by 8
Cao, M., Fay, F., Hotier, A., Domenichini, S., Alexandre, L., Ribes, C., Gazeau, F., Hillaireau, H., & Fattal, E. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.5c02390 · Cited by 7
Recent developments in antimicrobial polymers for biofilm inhibition
Kropp, G. A., McMillian, C. N., Mase, J. D., Kandagiri, S., Nowak, E. S., & Schulz, M. D. (2026) · Chemical Communications · doi:10.1039/d5cc06617d · Cited by 8
Nanoparticle Clearance and New Horizons in Engineered Drug Delivery
Mathis, B. J., Zaboronok, A., Shi, Y., Nagumo, Y., Nishiyama, H., & Hiramatsu, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040471 · Cited by 6
El‐Lateef, H. M. A., Khalaf, M. M., Abdelaziz, M. A., Taleb, M. F. A., Abdel-Halim, H. M. G., & Gouda, M. (2026) · International Journal of Adhesion and Adhesives · doi:10.1016/j.ijadhadh.2026.104423 · Cited by 6
Wang, F., Jiang, Y., Wang, L., Chen, Y., Zhang, Y., & Ma, M. (2022) · Nanomaterials · doi:10.3390/nano12101711 · Cited by 6
Krishna, Syeda, S., Parshad, B., Dhankhar, J., Sharma, A., Shrivastava, A., & Sharma, S. K. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113127 · Cited by 7
Petráková, M., Gorejová, R., Shepa, J., Macko, J., Kupková, M., Mičušík, M., Baláž, M., Hajdučková, V., Hudecová, P., Kožár, M., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c01002 · Cited by 6
Sardo, C., Auriemma, G., Mazzacano, C., Conte, C., Piccolo, V., Ciaglia, T., Denel‐Bobrowska, M., Olejniczak, A. B., Fiore, D., Proto, M., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16080971 · Cited by 6
“Therefore, it is crucial to investigate alternative materials that can overcome this restriction while still preserving the benefits linked with PEGylation [4–6].”
BackgroundSynthesis and self-assembly of cytidine- and guanosine-based copolymers
Chea, S., Schade, K., Reinicke, S., Bleul, R., & Rosencrantz, R. R. (2022) · Polymer Chemistry · doi:10.1039/d2py00615d · Cited by 7
pH‐Responsive Motors and their Interaction with RAW 264.7 Macrophages
Ramos‐Docampo, M. A., Qian, X., Ade, C., Marcelino, T. F., Ceccato, M., Foss, M., Hovorka, O., & Städler, B. (2022) · Advanced Materials Interfaces · doi:10.1002/admi.202201509 · Cited by 7
Qu, Y., Zhu, H., Lin, Z., Vanni, D., Bhangu, S. K., Dyett, B., Sani, M., Cortez‐Jugo, C., Caruso, F., & Cavalieri, F. (2023) · Chemistry of Materials · doi:10.1021/acs.chemmater.3c01378 · Cited by 6
Poly(Oxanorbornene)‐Protein Conjugates Prepared by Grafting‐to ROMP as Alternatives for PEG
Davis, E., Caparco, A. A., Steinmetz, N. F., & Pokorski, J. K. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300255 · Cited by 7
Polymeric Nanoparticles with a Sera-Derived Coating for Efficient Cancer Cell Uptake and Killing
Nierenberg, D., Flores, O., Fox, D. W., Sip, Y. Y. L., Finn, C. M., Ghozlan, H. H., Cox, A., McKinstry, K. K., Zhai, L., & Khaled, A. R. (2021) · ACS Omega · doi:10.1021/acsomega.0c05998 · Cited by 7
“7 The PEG density and chain length are also factors that could hinder cancer cell uptake.”
How to best handle vaccine decliners: scientific facts and psychological approach
Xantus, G. Z., Burke, D., & Kanizsai, P. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-139835 · Cited by 6
Kunte, N., Westerfield, M., McGraw, E., Choi, J., Akinsipe, T., Whitaker, S. K., Brannen, A. D., Panizzi, P. R., Tomich, J. M., & Avila, L. A. (2022) · Biomaterials Science · doi:10.1039/d2bm01314b · Cited by 8
Razzaghi, S., Vafaee, M., Kharazian, B., & Nasrollahpour, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-30493-3 · Cited by 6
Kazemi, M., Nazarabi, M., Niazi, Z., & Ashjari, M. (2021) · International Journal of Polymeric Materials · doi:10.1080/00914037.2021.1963723 · Cited by 6
Vijayalakshmi, K., Kavitha, A., & Ayyanaar, S. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114990 · Cited by 5
PEG-free Lipid Nanoparticles for mRNA Delivery: Superhydrophilic Sulfoxide Polymer Coatings
Choy, O. T., Fletcher, N. L., Fu, C., Vu, M. N., Ediriweera, G. R., Humphries, J., Hu, M., Kent, S. J., Cai, R., Chen, C., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c01899 · Cited by 8
Ko, E., Hu, J., Jeong, Y., Oh, C., Abdus, S. M., Lee, B.-J., & Park, C. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00795-x · Cited by 6
“To overcome these challenges, emerging strategies include cleavable PEG systems, alternative stealth polymers (e.g., polyglycerol, zwitterions), and targeted surface modification to balance stealth and cellular uptake (Hoang Thi et al. 2020; Zhang et al. 2021, 2024).”
Decoding Undesirable Inflammatory Responses of Nucleic Acid‐Delivering Lipid Nanoparticles
Hu, R., Dou, Y., Li, C., Mu, Y., Ouyang, H., Shen, W., & Zhang, J. (2026) · Advanced Science · doi:10.1002/advs.75548 · Cited by 6
Poly(ethylene glycol) based biomaterials
Özdemir, J. H., Cinfer, Ş. P., & Yoruç, A. B. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823797-7.00007-1 · Cited by 6
Lisiecka, M. Z. (2024) · Immunologic Research · doi:10.1007/s12026-024-09473-w · Cited by 6
“However, it is worth noting that all of these alternatives have certain limitations, and although they are considered safer compared to PEG, their effectiveness remains relatively low [40].”
Dave, R., Mofford, J., Hicks, E. A., Singh, A., Sheardown, H. D., & Hoare, T. R. (2024) · Nanoscale · doi:10.1039/d4nr03805c · Cited by 5
Navigating the future: Advancements in monoclonal antibody nanoparticle therapy for cancer
Kapare, H. S., Bhosale, M., & Bhole, R. P. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106495 · Cited by 8
Datta, S., Kronek, J., Nadova, Z., Timulakova, L., Minarčíková, A., & Miškovský, P. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114635 · Cited by 5
Büyüksungur, S., Tanır, T. E., Hasırcı, V., & Hasırcı, N. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00181 · Cited by 5
Lu, H., He, N., Zhang, L., You, Y., & Lv, Z. (2025) · Clinical ophthalmology · doi:10.2147/opth.s503273 · Cited by 6
Htwe, Y. Z. N., & Mamat, H. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2025.101823 · Cited by 5
Zhang, X., Chen, X., Chen, X., Wang, S., Wang, M., Geng, C., Xu, G., & Wang, S. (2023) · Polymer Chemistry · doi:10.1039/d3py00668a · Cited by 5
de Lima, P. H. C., Ribeiro-Viana, R., Plath, A. M. S., & Grillo, R. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02581k · Cited by 8
Clearance Pathways and Tumor Targeting of Imaging Nanoparticles for Diagnostics
Parikh, P. K., Parikh, N. H., Patel, J. K., & Pathak, Y. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-83395-4_17 · Cited by 6
Scherger, M., Pilger, Y. A., Komforth, P., Räder, H. J., & Nuhn, L. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01106 · Cited by 5
“9,10 For this reason, the generation of new reversible tethering strategies that could counteract these effects and the general development of alternatives to PEGylation are of great importance.”
BackgroundSavadkouhi, N., Salehi, P., Sepehri, H., Delphi, L., & Rafati, H. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.120258 · Cited by 5
Ogata, Y., Kuroiwa, T., & Ichikawa, S. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113360 · Cited by 4
Ferreira, I. G., de Oliveira, I. S., Bordon, K. D. C. F., Reis, M. B., Wiezel, G. A., Sanchez, C., Santos, L., Santos‐Filho, N. A., Pucca, M. B., Antunes, L. M. G., et al. (2023) · Toxins · doi:10.3390/toxins15080483 · Cited by 4
Alghamdi, M. A., Haider, M. A., Intagliata, S., Pittalà, V., Jagal, J., Haider, Y., Althaf, N., & Greish, K. F. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2323056 · Cited by 4
Daoud, L., Hoang, S., Milin-Moguerou, A., Eyer, J., Breton, T., Montembault, V., Fontaine, L., Passirani, C., Saulnier, P., & Krupka, O. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c01738 · Cited by 4
Robinson, J. J., Zhang, D., Basak, P., Vaidya, A., Chatterjee, S., Bian, X., Kim, M., Lian, X., Sun, Y., Guerrero, E. D., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00631 · Cited by 5
Yang, B., Gong, X., He, Y., & Zhou, F. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00231 · Cited by 5
A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide
Rodriguez, P., Pallais, J. P., He, R., Razzoli, M., McKee, J. L., Bock, H. A., McCorvy, J. D., Sham, Y. Y., DiMarchi, R., & Bartolomucci, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01177 · Cited by 5
Biteghe, F. A. N., Mungra, N., Malindi, Z., Chalomie, N. E. T., Stanislas, K. A., Yasmin‐Karim, S., Makrigiorgos, G. M., Chipidza, F., Akinrinmade, O. A., Sridhar, S., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71255 · Cited by 4
“…must, however, be noted that despite the wide use of PEGylated therapeutic proteins and previous assertions that PEG is a weak immunogen [52], research has recently indicated that there are potential risks associated with the development of anti-PEG antibodies and subsequent immune response [252].”
Wu, Y., Ieong, H., Wang, W., Wu, C., Lu, A., Pan, X., & Huang, Z. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111944 · Cited by 7
Tripathy, D., Rout, S. R., Saha, I., Halder, J., Rajwar, T. K., Rai, V. K., Pradhan, D., Mishra, A. K., Mahanty, R., Dash, P., et al. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128433361251009063909 · Cited by 6
Cai, Y., Nie, T., Luo, X., Wu, Y., & Wu, J. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.01.043 · Cited by 4
Lee, S. Y., Lee, S. H., Tor, Y. S., Yong, P. V. C., & Ho, K. L. (2026) · BioNanoScience · doi:10.1007/s12668-025-02384-6 · Cited by 5
Dreier, P., Bockhard, C., Seibel, D., Soltwedel, О., Matthes, R., Linden, G. M., Schmidt, J., Göbel, D., Endres, T., Scheiger, J. M., et al. (2026) · Chemical Science · doi:10.1039/d6sc00169f · Cited by 4
Karakus, O. O., Godugu, K., Salaheldin, T. A., Fujioka, K., & Mousa, S. A. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0230 · Cited by 4
Rahman, M., Afzal, O., Ullah, S. N. M. N., Alshahrani, M. Y., Alkhathami, A. G., Sahoo, A., Altamimi, A. S. A., Almalki, W. H., Almujri, S. S., abdulrahman, A., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105326 · Cited by 6
Abodunrin, O. D., Bricha, M., & Mabrouk, K. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95486-0.00028-4 · Cited by 6
Maeshima, R., Tagalakis, A. D., Gyftaki-Venieri, D. A., Jones, S. A., Rye, P. D., Tøndervik, A., Åstrand, O. A. H., & Hart, S. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400510 · Cited by 5
Ultrashort Peptides as Stabilizing Agents for Colloidal Nanogold
Figueroa, J. D., Schejtman, S. D. G., Tu, R., Muñoz, M. A., Salas-Sepúlveda, F., Poblete, H., Langlois, M., Suuronen, E. J., & Alarcon, E. I. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c17794 · Cited by 4
Cai, Z., Fu, F., Zhu, S., Wu, J., Han, X., Jiang, S., Qian, Z., & Wang, C. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.162443 · Cited by 4
Maiti, B., Nandi, M., Bonardd, S., Franco, L., Puiggalí, J., Enshaei, H., Alemán, C., & Díaz, D. D. (2021) · ChemPlusChem · doi:10.1002/cplu.202100451 · Cited by 4
Microbial transglutaminase-mediated formation of erythropoietin-polyester conjugates
Alaneed, R., Naumann, M., Pietzsch, M., & Kreßler, J. (2022) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2022.01.001 · Cited by 4
Chemische Ansätze für synthetische Wirkstofftransportsysteme für systemische Anwendungen
Braatz, D., Cherri, M., Tully, M., Dimde, M., Ma, G., Mohammadifar, E., Reisbeck, F., Ahmadi, V., Schirner, M., & Haag, R. (2022) · Angewandte Chemie · doi:10.1002/ange.202203942 · Cited by 4
Amphiphilic Copolymer-Lipid Chimeric Nanosystems as DNA Vectors
Chrysostomou, V., Foryś, A., Trzebicka, B., Demetzos, C., & Pispas, S. (2022) · Polymers · doi:10.3390/polym14224901 · Cited by 5
Nucleic Acid Aptamers: From Basic Research to Clinical Applications
Otte, D. M., Choukeife, M., Patwari, T., & Mayer, G. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_25-1 · Cited by 5
de Oliveira, F. A., Batista, C. C. S., Albuquerque, L. J. C., Černoch, P., Steinhart, M., Sincari, V., Jäger, A., Jäger, E., & Giacomelli, F. C. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.12.129 · Cited by 4
Pandey, P., Chaturvedi, S., Gumathannavar, R., Shirolkar, M. M., Kanuru, V. K., Kulkarni, A., & Moh, S.-H. (2023) · ChemistryOpen · doi:10.1002/open.202200200 · Cited by 4
Vesicular Diagnostics: A Spotlight on Lactate- and Ammonia-Sensing Systems
Matoori, S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00042 · Cited by 4
Molecular Modeling in Drug Delivery: Polymer Protective Coatings as Case Study
Bunker, A., & Kehrein, J. (2024) · Wiley eBooks · doi:10.1002/9781119987260.ch5 · Cited by 5
Poly(lactic-co-glycolic acid) in drug delivery and tissue engineering applications
Ramesh, P., Ramajayam, K., Beena, M., Ganesan, S., & Palaniappan, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95233-0.00013-3 · Cited by 7
Multiplexing Label-Free Polymeric Nanocarriers via Antipolymer Antibodies
Humphries, J., Hobson‐Peters, J., Ghosh, S., Howard, C. B., Huda, P., Bell, C. A., Fletcher, N. L., Kempe, K., & Thurecht, K. J. (2025) · ACS Sensors · doi:10.1021/acssensors.4c03184 · Cited by 3
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.